The first product was launched in 2018 and with the help of the fresh capital the company will broaden their product portfolio with new microbiom studies. Moreover the company culture of the DNA sequencing company is focused by finding new employees and international partner. For us the investment is one in the most booming sector of today. As the microbiom analyses helps people’s wellbeing and had a large impact on people’s health the company has a natural fit to yabeo’s HealthTech portfolio.